Conclusions:
The authors concluded that an immunemediated demyelinating polyneuropathy is a well-recognized entity in diabetic patients, and for those with the clinical and EP features and significant functional deficits, immunomodulating therapy should be considered.
This is a preview of subscription content, log in via an institution to check access.
References
Sharma KR, Cross J, Farronay O, et al.: Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002, 59:758–765.
Sharma KR, Cross J, Ayyar DR, et al.: Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002, 59:751–757.
Nicolas G, Maisonobe T, Le Forestier N, et al.: Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002, 25:26–30.
Rotta FT, Sussman AT, Bradley WG, et al.: The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000, 173:129–139.
Cocito D, Ciaramitaro P, Isoardo G, et al.: Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol 2002, 249:719–722.
Hughes RA: Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat 2002, 200:331–339.
Rights and permissions
About this article
Cite this article
Boulton, A.J.M. Chronic inflammatory demyelinating polyneuropathy and diabetes. Curr Diab Rep 3, 437–438 (2003). https://doi.org/10.1007/s11892-003-0004-2
Issue Date:
DOI: https://doi.org/10.1007/s11892-003-0004-2